Gemcitabine Hydrochloride is named as a drug or biological intervention in 16 clinical trials in our China trial register, 13 of which are recruiting. Lead sponsors include BeBetter Med Inc (2), Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (2) and Shanghai Hengrui Pharmaceutical Co., Ltd. (2). Registered phases: Phase 3, Phase 1/2, Phase 2/3 and Phase 2. Conditions studied include Breast Cancer; Relapsed/Refractory Diffuse Large B-Cell Lymphoma; Locally Advanced Triple-negative Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 1 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 1 |
| Locally Advanced Triple-negative Breast Cancer | 1 |
| Metastatic Triple-negative Breast Cancer | 1 |
| Advanced Solid Tumour | 1 |
| Advanced Pancreatic Cancer | 1 |
| EBV Infection | 1 |
| Stage II Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Stage III Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Stage IVA Nasopharyngeal Carcinoma AJCC v7 | 1 |
| Diffuse Large Cell B-lymphoma | 1 |
| Advanced Urothelial Carcinoma | 1 |
| Ovarian Cancer | 1 |
| Urothelial Carcinoma | 1 |
| Solid Tumor | 1 |
| NMIBC | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| Fludzoparib" and Anti-angiogenic | 1 |
| HRD-positive/HER2-negative Advanced Breast Cancer | 1 |
| Metastatic Pancreatic Ductal Adenocarcinoma | 1 |
| Diffuse Large B-cell Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| BeBetter Med Inc | 2 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 2 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 1 |
| Nanjing Leads Biolabs Co.,Ltd | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| NRG Oncology | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| BeiGene | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Register | Gemcitabine Hydrochloride trials |
|---|---|
| Clinical trials in China | 16 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabine Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabine Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.